Drug Trial Radar · NCT01294592
Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement
Last checked: Nov 20, 2026Latest source record: Aug 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
742
Actual
Start
Dec 22, 2010
Primary completion
Oct 17, 2013
Study completion Oct 17, 2013
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 11, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study FDC114615 is a two year, multi-centre, randomised, open-label trial to assess the efficacy of Dutasteride plus tamsulosin when compared to the standard practice of watchful waiting, with a defined escalation to tamsulosin in treatment naive men with symptomatic benign prostate hyperplasia (BPH). Once consented, each subject will undergo screening procedures to ensure the prostate volume and post void residual are within eligible range. If all entry criteria are met, subjects will be randomised (1:1) to receive Dutasteride plus tamsulosin with lifestyle advice or watchful waiting, with lifestyle advice, with a defined escalation to tamsulosin. Escalation will be initiated when no improvement from baseline is scored using the International Prostate Symptom Score (version 2) (IPSS) questionnaire. After randomisation, the subjects return to site at one month, then every 13 weeks until two years of treatment is complete or they are withdrawn. Key assessments, such as Adverse Events (AE's) and concomitant medication monitoring and completion of the quality of life questionnaires are performed at each visit and the data recorded.
Conditions
- Prostatic Hyperplasia
Interventions
Dutasteride plus tamsulosinDrug
Take 1 capsule daily
tamsulosinDrug
Take 1 capsule daily when escalation criteria met
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the Last Observation Carried Forward (LOCF) ApproachTime frame: Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24
Locations
80 sites in 8 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Aigrefeuille-sur-Maine, France
GSK Investigational Site
Angers, France
GSK Investigational Site
Angers, France
GSK Investigational Site
Corsept, France
GSK Investigational Site
La Montagne, France
GSK Investigational Site
La Rochelle, France
GSK Investigational Site
Laval, France
GSK Investigational Site
Le Temple-de-Bretagne, France
GSK Investigational Site
Mûrs-Erigné, France
GSK Investigational Site
Nantes, France
GSK Investigational Site
Nieul-sur-Mer, France
GSK Investigational Site
Sautron, France
GSK Investigational Site
Thouars, France
GSK Investigational Site
Tiercé, France
GSK Investigational Site
Vihiers, France
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Eisleben Lutherstadt, Germany
GSK Investigational Site
Aichach, Bavaria, Germany
GSK Investigational Site
Nuremberg, Bavaria, Germany
GSK Investigational Site
Hagenow, Brandenburg, Germany
GSK Investigational Site
Oranienburg, Brandenburg, Germany
GSK Investigational Site
Strausberg, Brandenburg, Germany
GSK Investigational Site
Marburg, Hesse, Germany
GSK Investigational Site
Buchholz, Lower Saxony, Germany
GSK Investigational Site
Essen, North Rhine-Westphalia, Germany
GSK Investigational Site
Leipzig, Saxony, Germany
GSK Investigational Site
Hettstedt, Saxony-Anhalt, Germany
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany
GSK Investigational Site
Argos, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Larissa, Greece
GSK Investigational Site
Pátrai, Greece
GSK Investigational Site
Rhodes, Greece
GSK Investigational Site
Thessaloniki, Greece
GSK Investigational Site
Thessaloniki, Greece
GSK Investigational Site
Vasto (CH), Abruzzo, Italy
GSK Investigational Site
Foggia, Apulia, Italy
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.